Delivery Order SPE2DR25D2014-SPE2DR26FZ61A
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,259.34 to AmerisourceBergen Drug Corp for the supply of Norditropin FlexPro 10 mg/1.5 mL, a human growth hormone medication. This competitively awarded, firm fixed-price delivery order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,200.56 to AmerisourceBergen Drug Corp for Norditropin FlexPro 15 mg/1.5 mL pharmaceutical products, with delivery scheduled for completion by November 18, 2025. This competitively awarded, firm fixed-price delivery order leverages AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle that extends through...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Norditropin FlexPro 15 mg/1.5 mL, a human growth hormone medication. This firm fixed-price delivery order, valued at $2,208.18, is set to be completed by November 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competitive delivery against AmerisourceBergen's existing indefinite delivery contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,425.04 to AmerisourceBergen Drug Corp for Norditropin Flexpro 10 mg/1.5 mL, a human growth hormone medication. The contract was awarded on November 14, 2025, with an ultimate completion date of November 17, 2025, under firm fixed pricing with no set-aside designation. Performance of this delivery order will occur at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $1,047.66 delivery order to AmerisourceBergen Drug Corp for Norditropin FlexPro 15 mg/1.5 mL pharmaceutical product on November 7, 2025, with an ultimate completion date of November 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,981.40 to AmerisourceBergen Drug Corp for Norditropin Flexpro 15 mg/1.5 ml pharmaceutical product, with an ultimate completion date of October 30, 2025. This non-set-aside, competitively awarded contract employs firm fixed price pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's facility in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,971.47 to AmerisourceBergen Drug Corp for Norditropin FlexPro 15 mg/1.5 mL, a human growth hormone medication. The contract, awarded on August 12, 2025, with completion targeted for August 13, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, executed this order through its Corporate Office division. The place of...
- The Defense Logistics Agency awarded a $7,360.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Norditropin FlexPro 10 mg/1.5 ml pharmaceutical products, with an ultimate completion date of November 10, 2025. This non-set-aside competitive award was issued on November 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for Norditropin FlexPro 15 mg/1.5 mL pharmaceutical products, with a ceiling value of $2,202.89. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by June 27, 2025. The delivery order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This award represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $3,557.63 to AmerisourceBergen Drug Corp for Norditropin FlexPro 10 mg/1.5 mL, a human growth hormone medication. This competitively awarded, firm fixed-price delivery order was issued on November 17, 2025, with an ultimate completion date of November 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ61ADelivery Order
The Defense Logistics Agency (DLA) awarded a $3,852.66 delivery order to AmerisourceBergen Drug Corp for Norditropin Flexpro 10 mg/1.5 ml pharmaceutical products, with completion targeted for November 4, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, holds a $999,999,999.00 prime IDC with DLA Troop Support Medical (contract SPE2DX) extending through December 2026. This comprehensive vehicle enables the company to supply a broad range of pharmaceuticals and medical supplies to support military healthcare programs globally, including specialty medications, vaccines, and medical devices across multiple therapeutic domains. The current delivery order for human growth hormone treatment exemplifies the company's role in supporting Defense Health Agency procurement and broader federal healthcare initiatives through its established pharmaceutical prime vendor relationship.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 11/3/25 |